Published February 5, 2020 Background Capivasertib (AZD5363) is an oral inhibitor of AKT and by that it influences cell division, apoptosis and cell metabolism. The FAKTION study investigated whether the…
Published on January 21, 2020 Background In this trial, 137 cancer patients with NO AVAILABLE STANDARD THERAPEUTIC OPTIONS were treated with the combination of Lenvima plus Keytruda. Eligible patients had…
Background - A woman in her sixties was diagnosed about two years ago with Small Cell Lung Cancer, SCLC (15% of all lung cancer patients are diagnosed with this type…
Background - 6 months ago, M.N., 38, was diagnosed with an extremely rare and aggressive type of cancer. A cancer that progresses tremendously rapidly in the body, very deadly. Out…
Intended for recurrent Glioblastoma, GBM, patients or patients with DIPG brain tumor with H3 K27M mutation We will be happy to help you access the world's most advanced treatments both…
No sign of cancer! Groce has been a part of a clinical trial since his diagnosis four-plus years ago and the results have been tremendous –just recently, his MRI and…
Background The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life…
PURPOSE OF THE STUDY The trial was designed to evaluate the safety and efficacy of adding Capivasertib to Taxol as first-line therapy for metastatic TNBC patients. PATIENTS AND METHODS A…
Background This phase II trial was designed to evaluate the benefit of Keytruda® plus Zolinza® for recurrent Head and Neck Squamous Cell Carcinoma, HNSCC and Salivary Gland Cancer, SGC. Among…
Background Urothelial cancer accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra. Tremelimumab is an immunotherapy treatment that helps the…